Patent ID: 11885812
Assignee: EXAGEN INC.
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 5:
6. A method for treating systemic lupus erythematosus in a human subject in need thereof, wherein the human subject is negative for systemic lupus erythematosus based on a level of double-stranded DNA antibody; the method comprising:
(a) measuring a level of erythrocyte-bound complement component C4d (EC4d) marker in a blood sample obtained from the patient;
(b) measuring a level of B-lymphocyte-bound C4d complement component (BC4d) marker in the blood sample;
(c) measuring a level of anti-nuclear antibody (ANA) in the blood sample;
(d) determining a systemic lupus erythematosus risk score by adjusting the level of EC4d, the level of BC4d, and the level of ANA by a transformation analysis;
(e) determining that the human subject has systemic lupus erythematosus based on the systemic lupus erythematosus risk score; and
(f) treating the human subject from step (e) that has systemic lupus erythematosus based on the systemic lupus erythematosus risk score with an effective amount of cyclophosphamide, a corticosteroid, mycophenolate, methotrexate, azathioprine, leflunomide, belimumab, or hydroxychloroquine.